Minister of Research and Technology Visits Three Kalbe Group R&D Laboratories
Minister of Research and Technology Head of the National Research and Innovation Agency (Menristek BRIN), Prof. Bambang PS Brodjonegoro, Ph.D. along with his entourage visited three Kalbe Group factories to observe the research and development laboratory facilities as well as the production facilities. The visit began at the Stem Cell and Cancer Institute (SCI) located in Pulomas, East Jakarta, followed by the factories of PT Kalbe Farma Tbk and PT Kalbio Global Medika in the Delta Silicon Industrial Zone, Cikarang.
The visit of the Minister of Research and Technology and Head of BRIN was received by the board of directors of PT Kalbe Farma including President Director Vidjongtius, Directors Michael B. Nugroho and Sie Djohan, and the Founder of Kalbe, Dr. Boenjamin Setiawan Ph.D.
During his visit, the Minister said that he hoped the Research and Development (R&D) center in a company could be made into one area so that it would make it easier for the Government to oversee the R&D process. “We at Menristek also encourage Science Techno Park, whose concepts are all-in-one area so that the business world can be more involved in research,” said Prof. Bambang. “Furthermore, tax reduction can also encourage greater investment in R&D, that shall benefit Kalbe,” he added.
In his response, Vidjongtius, President Director of PT Kalbe Farma Tbk said, “Currently one of Kalbe's focuses is the development of red ginger, to produce good quality red ginger. A part of the extraction of it shall be used for Kalbe products, as well as being exported as extracts. For the specific research, we are collaborating with several universities, one of them is Surabaya University by building a tissue culture laboratory.”
Kalbe has built R&D facilities in the fields of pharmaceutical products, stem cells and biotechnology-based products. Kalbe also provides funding for research projects through the Ristek-Kalbe Science Awards and Kalbe Junior Scientist Award, as well as support for other research activities. Kalbe is aware that an innovation climate will be built if there is a collaborative and partnership effort between elements of government, academia and business.
KGM at a Glance
Kalbio Global Medika (KGM) is one of the first and the pioneer of biopharmaceuticals in Indonesia, established in 2014 and inaugurated officially in 2018 by the President of the Republic of Indonesia, Ir. Joko Widodo. KGM is part of the Kalbe Group, a subsidiary of PT Kalbe Genexine Biologics (KGbio), which is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside US/Canada, Western Europe, and China. KGM is an Innovative CDMO, equipped with CMC and scale-up capabilities plugged into Boston biotech ecosystem and state-of-the-art facility to enhance efficiency and productivity. With API manufacturing, formulation, fill and finish capabilities of biosimilar and novel biologics, averaging 10 million units of syringes, cartridges, and vials, KGM supplies local and international markets.
Kalbe at a Glance
PT Kalbe Farma Tbk (Kalbe) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle a portfolio of dependable and various brands: the prescription pharmaceutical division, the health products division that handles over-the-counter drugs, multivitamins, and ready-to-serve supplemental drinks, the nutritions division, and the distribution & logistics division.
Kalbe has also developed a B2B-based digital services ecosystem for the society: EMOS and KlikDokter, a B2C service. EMOS is an order management application system that helps distribution channels perform their stock or supply chain management actions. KlikDokter is a digital platform for healthcare services focusing on telemedicine, which provides health consultation and products that are needed by the society.
Kalbe now has more than 40 subsidiaries and 15 international-standard production facilities, supported by around 16,000 employees in 76 branches throughout Indonesia. Kalbe’s shares have been listed in Indonesia Stock Exchange/Bursa Efek Indonesia (IDX:KLBF) since 1991.
Reference:
Minister of Research and Technology Visits Three Kalbe Group Research and Development Laboratories